HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Beijing Continent Pharmaceuticals / Equity Capital Markets

Beijing Continent Pharmaceuticals (CPH HK)

<ul>
<li>With favorable policies and improved intellectual property protection, investors' attitude towards rare diseases in China has changed significantly and become more interested in this field.</li>
<li>Since no new candidates would be commercialized until 2024, <a href="https://www.smartkarma.com/entities/beijing-continent-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:35664:1" rel="noopener">Beijing Continent Pharmaceuticals (CPH HK)</a> could face increasing competition and financial pressure. The breakthrough point is to develop overseas markets.</li>
<li>In terms of valuation, Continent is better than <a href="https://www.smartkarma.com/entities/canbridge-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:33783:1" rel="noopener">CANbridge Pharmaceuticals (1228 HK)</a>, so it is expected to have higher valuation than CANbridge after listing.</li>
</ul>


With favorable policies and improved intellectual property protection, investors' attitude towards rare diseases in China has changed significantly and become more interested in this field.
Since no new candidates would be commercialized until 2024, Beijing Continent Pharmaceuticals (CPH HK) could face increasing competition and financial pressure. The breakthrough point is to develop overseas markets.
In terms of valuation, Continent is better than CANbridge Pharmaceuticals (1228 HK), so it is expected to have higher valuation than CANbridge after listing.


Pre-IPO Beijing Continent Pharmaceuticals - The Orphan Drug Pioneer Needs to Expand Overseas

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Beijing Continent Pharmaceuticals - The Orphan Drug Pioneer Needs to Expand Overseas

Despite promising orphan drug market, with no new drugs commercialized until 2024, Continent will face increasing competition/financial pressure....

Xinyao (Criss) Wang